Fresenius Medical Care (ETR:FME) Shares Pass Above Two Hundred Day Moving Average - Here's What Happened

Market Beat
2025.03.22 01:10
portai
I'm PortAI, I can summarize articles.

Fresenius Medical Care (ETR:FME) shares have surpassed their 200-day moving average, trading at €44.07 ($47.90) with a volume of 465,526 shares. The stock has a market capitalization of $13.39 billion and a P/E ratio of 20.32. The company specializes in dialysis services for renal disease patients globally. Despite the positive movement, analysts currently rate the stock as a Hold, suggesting there are better investment options available.

Fresenius Medical Care AG (ETR:FME - Get Free Report) shares passed above its 200-day moving average during trading on Tuesday . The stock has a 200-day moving average of €41.84 ($45.48) and traded as high as €44.45 ($48.32). Fresenius Medical Care shares last traded at €44.07 ($47.90), with a volume of 465,526 shares.

Get Fresenius Medical Care alerts:

Fresenius Medical Care Trading Up 1.5 %

The company has a debt-to-equity ratio of 82.24, a quick ratio of 0.80 and a current ratio of 1.37. The stock has a market capitalization of $13.39 billion, a P/E ratio of 20.32, a price-to-earnings-growth ratio of 0.42 and a beta of 0.86. The business has a 50 day simple moving average of €45.29 and a 200-day simple moving average of €41.86.

About Fresenius Medical Care

(Get Free Report)

Fresenius Medical Care AG provides dialysis and related services for individuals with renal diseases in Germany, North America, and internationally. The company offers dialysis treatment and related laboratory and diagnostic services through a network of outpatient dialysis clinics; materials, training, and patient support services comprising clinical monitoring, follow-up assistance, and arranging for delivery of the supplies to the patient's residence; and dialysis services under contract to hospitals in the United States for the hospitalized end-stage renal disease (ESRD) patients and for patients suffering from acute kidney failure.

See Also

  • Five stocks we like better than Fresenius Medical Care
  • Are These Liquid Natural Gas Stocks Ready For An Upside Bounce?
  • Everything About Amazon Stock Signals a Buy—Time to Load Up?
  • How to Short Nasdaq: An Easy-to-Follow Guide
  • 5 Reasons Five Below’s Stock Price Is Heading Higher This Year
  • Unveiling The Power Of VWAP: A Key Indicator For Traders
  • Broadcom: Why the Chip Stock Remains a Top Long-Term AI Play

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in Fresenius Medical Care Right Now?

Before you consider Fresenius Medical Care, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Fresenius Medical Care wasn't on the list.

While Fresenius Medical Care currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here